Novel pharmacological therapies in development.

Area of Science:

• Neurology
• Pharmacology
• Drug Development

Background:

• Epilepsy treatment has historically focused on common forms, but a shift towards rare, drug-resistant syndromes is evident.
• Unmet therapeutic needs are greatest in patients with developmental and epileptic encephalopathies.
• Over 30 novel treatments are progressing through clinical development.

Purpose of the Study:

• To review the progress of new pharmacological treatments for epilepsy.
• To focus on agents currently in clinical development pipelines.
• To highlight innovative therapeutic approaches and their potential impact.

Main Methods:

• Review of clinical development pipelines for epilepsy treatments.
• Analysis of novel therapeutic modalities including small molecules, nucleic acid-based therapies, stem cells, and microbiome-targeting bacteria.
• Assessment of repurposed drugs for epilepsy indications.

Main Results:

• Over 30 distinct treatments are in clinical development, encompassing diverse mechanisms of action.
• A significant focus is on rare epilepsies, particularly developmental and epileptic encephalopathies.
• Most compounds are in early development; robust efficacy data from large trials are limited, with only two agents (azetukalner, Staccato alprazolam) showing positive results in randomized controlled trials.

Conclusions:

• Innovative drug discovery paradigms are yielding novel, etiology-targeting epilepsy treatments with potential disease-modifying effects.
• While high-quality evidence is still emerging, these advancements offer hope for significant therapeutic breakthroughs.
• Life-changing therapies for drug-resistant epilepsies may become widely available in the coming years.